epocrates

Drug Updates: Week of March 9, 2026

March 16, 2026

Here's a quick roundup of last week’s new drugs and updates in epocrates.

Brand drugs

Bysanti (milsaperidone)

• Read more: FDA OKs Bysanti for bipolar I disorder and schizophrenia

Yuviwel (navepegritide)

• Read more: FDA grants accelerated approval to Yuviwel for achondroplasia in children

Vykoura (leucovorin)

First-time generic

dalbavancin

• Equivalent brand: Dalvance

Contrast agents

iopamidol

iopamidol intrathecal

Conray (iothalamate meglumine)

Cysto-Conray II (iothalamate meglumine)

Ultravist (iopromide)

Investigational new drug (IND)

Rusfertide

• Proposed indication: polycythemia vera
• Read the press release

Drugs with new or expanded indications

Dupixent (dupilumab)

• New indications: 1) allergic fungal rhinosinusitis in adults and pediatric pts 6 years and older weighing >15 kg; and 2) maintenance tx for asthma with concurrent allergic fungal rhinosinusitis in adults and pediatric pts 12 years and older weighing >60 kg
• Read more: FDA approves Dupixent for allergic fungal rhinosinusitis

Keytruda (pembrolizumab) & Keytruda Qlex (pembrolizumab/berahyaluronidase alfa)

• New indication: PD-L1-expressing ovarian CA in adults
• Read more: FDA OKs immunotherapy regimen for platinum-resistant ovarian cancer

Palynziq (pegvaliase-pqpz)

• Expanded indication: phenylketonuria (PKU) in pediatric pts 12 years and older
• Read more: Palynziq now approved for phenylketonuria in adolescents

Sogroya (somapacitan-beco)

• New indications: 1) SGA-associated short stature in pediatric pts 2.5 years and older; 2) Noonan syndrome-associated growth failure in pediatric pts 2.5 years and older; and 3) idiopathic short stature in pediatric pts 2.5 years and older
• Read more: FDA greenlights Sogroya for 3 new pediatric indications